APA (7th ed.) Citation

SB, K., F, M., A, K., A, B., R, L., T, T., . . . J, B. (2019). First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. Targeted oncology, 14(5), 591. https://doi.org/10.1007/s11523-019-00670-4

Chicago Style (17th ed.) Citation

SB, Kim, et al. "First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer." Targeted Oncology 14, no. 5 (2019): 591. https://doi.org/10.1007/s11523-019-00670-4.

MLA (9th ed.) Citation

SB, Kim, et al. "First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer." Targeted Oncology, vol. 14, no. 5, 2019, p. 591, https://doi.org/10.1007/s11523-019-00670-4.